Concepedia

Publication | Closed Access

Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain

DOI

59

Citations

0

References

2011

Year

Stein Kaasa, Kristin Moksnes, Thomas Nolte, Danièle Lefebvre-Kuntz, Lars Popper, Hans G. Kress
Journal of Opioid Management

Abstract

INFS at doses of 50, 100, and 200 microg showed a short T(max) and was well tolerated in patients with cancer. These results support INFS use in patients with cancer suffering from BTP.